Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) is making significant strides in its mission to combat cancer by advancing its preclinical candidate ONC010 toward clinical development. The nanoparticle-encapsulated PNKP inhibitor is designed to disrupt DNA-repair mechanisms that cancer cells rely on for survival and resistance to treatment. The company recently reported the completion of a 300-gram API scale-up with approximately 99.3% purity, a critical milestone for ensuring a consistent and high-quality supply of the drug candidate for future clinical trials.
To support this scale-up and other development activities, Onco-Innovations has expanded its manufacturing capabilities through a partnership with Nanosoft Polymers. This collaboration is expected to enhance production capacity and optimize the formulation of ONC010. Additionally, the company is progressing with metabolism studies, analytical development, licensing agreements, and other Investigational New Drug (IND)-enabling activities. These steps are essential for preparing the candidate for regulatory submission and eventual human testing.
Financially, Onco-Innovations has arranged approximately CAD$5 million in institutional financing, which will be released in 18 monthly tranches. This funding is intended to support the development of ONC010, the SynoGraph platform, and general corporate needs. While the actual proceeds may differ from the stated notional amount, the financing provides a steady stream of capital to advance the company's pipeline. The recent appointment of Dave Antony as Chief Financial Officer further strengthens the company's financial and corporate expertise as it navigates the complex path to clinical trials.
The company's ultimate goal is to initiate a Phase 1 study of ONC010 in Australia. This planned trial will evaluate the safety, tolerability, and preliminary efficacy of the drug candidate in patients with solid tumors. If successful, ONC010 could offer a novel approach to overcoming treatment resistance, a major challenge in oncology. By targeting PNKP, an enzyme involved in DNA repair, ONC010 aims to sensitize cancer cells to existing therapies, potentially improving outcomes for patients who have not responded to standard treatments.
Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumors, positioning it to potentially address a broad range of cancers. The company's progress in manufacturing, regulatory, and financial areas demonstrates its commitment to translating preclinical research into clinical reality. For more information, visit the company's website at https://oncoinnovations.com/. Investors can also stay updated on the latest news and developments by visiting the company's newsroom at https://nnw.fm/ONNVF. To view the full article referenced in this announcement, visit https://nnw.fm/YPLe7.
This news is disseminated by NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides a vast network of wire solutions via InvestorWire to reach target markets, demographics, and industries. The platform also offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. For a full array of tailored corporate communications solutions, visit the NetworkNewsWire website. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
